SIgN hosts three core research programs in Infectious Disease, Cancer and Immune Dysfunctions. All research groups within these programs benefit from access to the SIgN Immunomonitoring Platform that provides world-leading expertise and state-of-the-art technologies for flow cytometry/cell sorting, Cytometry by Time-of-Flight (CyTOF), multiplexed soluble protein assays, immunogenomics, single-cell analytics and immunoinformatics. SIgN researchers also have access to high-class functional immune imaging facilities, an animal facility and preclinical mouse models of human disease and a human monoclonal antibody platform. Together, these technologies enable our researchers to build a complete research picture from the DNA and molecular level, through to models of human diseases and human clinical cohort studies.

The SIgN Immunomonitoring Platform actively supports clinical trial monitoring, cohort and clinical studies, in collaboration with multiple research, clinical and industrial partners. Some current examples include:

• A Phase IV clinical trial on the immune responsiveness in Flu-vaccinated Elderly
• Oncology studies in mouse and man aimed at biomarker discovery
• A large-scale clinical study of heart failure
• The Singapore Longitudinal Aging Study
• The Cohort Study of Atopy and Allergy 
• The Growing Up Towards Healthy Outcomes (GUSTO) study
• The SG90 Nonagenarian Study 
• Various clinical studies in areas of dengue virus, hepatitis B virus, irritable bowel disease, cancer and heart failure